3C Therapeutics

Executive Summary

3C Therapeutics is a private, preclinical-stage biotechnology company headquartered in San Diego, CA, founded in 2018. The company is focused on developing targeted cancer therapies by leveraging its proprietary platform to design both small molecules and biologics. With a lean team of 10–50 employees, 3C Therapeutics operates in the competitive oncology space, aiming to address unmet medical needs through novel mechanisms. While the company has not disclosed its total funding, valuation, or specific pipeline candidates, its dual modality approach suggests a versatile strategy for tackling diverse cancer targets. The preclinical stage indicates that the company is still in the early phases of drug development, with no reported FDA approvals or commercial products to date. However, its proprietary platform may offer differentiation if validated through upcoming studies.

Upcoming Catalysts (preview)

• Q1 2027Lead Program IND Filing20% success
• Q4 2026Preclinical Proof-of-Concept Data Release40% success
• H2 2026Series A Financing Announcement60% success